Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UCB Trims Down With SHAPE Program

This article was originally published in The Pink Sheet Daily

Executive Summary

Drug maker announces plan to cut 2,000 jobs, or 17 percent of its workforce, ahead of Keppra patent expiry.

You may also be interested in...



UCB’s New Strategy Takes SHAPE As GSK Buys Out Emerging Markets

For about $670 million, GSK acquires UCB drugs and infrastructure in several dozen non-BRIC markets.

UCB’s New Strategy Takes SHAPE As GSK Buys Out Emerging Markets

For about $670 million, GSK acquires UCB drugs and infrastructure in several dozen non-BRIC markets.

UCB Takes Back EU Try With Vimpat

Withdrawal follows July “not approvable” letter in diabetic pain.

Related Content

Topics

UsernamePublicRestriction

Register

ID1132679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel